PAGE 16
HIV NUTRITION UPDATE
VOLUME 7, ISSUE 6

(Return to page 15)
 
By William Palumbo, MS, RD, CDN
Therapeutic Category: Antilipemic Agent, Fibric Acid

Use: Adjunct to diet therapy for the treatment of adults with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort.

Contraindications: Hypersensitivity to fenofibrate or any component of the formulation, hepatic or severe renal dysfunction including primary biliary cirrhosis and unexplained liver function abnormalities; pre-existing gallbladder disease. Patients should avoid alcohol.

Adverse Reactions: abdominal pain, constipation, abnormal liver function tests, creatine phosphokinase increased, cholecystitis, cholelithiasis, gastritis, vomiting, hypoglycemia, and kidney function abnormalities.
 
 
Mechanism of Action: TriCor is believed to increase very low-density lipoprotein cholesterol (VLDL) catabolism by enhancing the synthesis of lipoprotein lipase; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30-60%.

Pharmacodynamics:
Absorption: 60-90% when given with meals.
Distribution: Widely to most tissues except brain or eye; concentrates in liver, kidneys, and gut.
Protein Binding: >99%
Metabolism: Metabolized to its active form, fenofibric acid, by tissue and plasma esterases.
Time to Peak: 4-6 hours
Excretion: Urine (60-93% metabolites); feces (5-25%).

Nutrition: Take with food to increase absorption and decrease gastrointestinal distress.

Administration: 6-8 weeks of therapy is required to determine efficacy.

Monitoring Parameters: Total serum cholesterol and triglyceride concentration, low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) levels should be monitored periodically. Serum transaminases should be monitored every 3 months.

Dosage Forms: Capsule- 67 mg  Tablet- 54 mg, 160 mg

Additional Information: Visit the TriCor Web Site, which has  information on TriCor and cholesterol. The web site offers a one-page information sheet called 10 Quick Facts About Cholesterol Management and a brochure called Keeping Track of Your Cholesterol and Triglycerides. 
 
 

 

"TriCor is believed to increase very low-density lipoprotein cholesterol (VLDL) catabolism by enhancing the synthesis of lipoprotein lipase; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30-60%."
References:
 
  • Lacy C, et al. Drug Information Handbook. 2002-2003. 10th Edition.Lexi-Comp, Inc: Hudson, OH. 2002: 548-550.
(Foward to page 17)


 

No part of this newsletter may be reproduced in any form without permission from the publisher. Copyright 2003 HIV ReSources, Inc. Email: subscriptions@hivresources.com


 
 
 

 
 
Copyright 2003 HIV ReSources, Inc. Sharing this newsletter in any form with non-subscribers is strictly prohibited. Library/Institution subscribers are permitted to share HIV Nutrition Update html newsletter pages with up to five (5) employees or volunteers. NO other redistribution allowed. 
 
Please Help To Keep This Page Updated By Notifying
The Webmaster If You Find A Link That's Outdated!
 
HIV ReSources, Inc.
PO Box 39385
Fort Lauderdale, FL
33339-9385
USA
 
© 2003  HIV ReSources, Inc.
Any use of the information presented herein is done strictly at your own risk.
No responsibility is implied or intended on the part of HIV ReSources Inc,
the editor, or the publisher. Information on this site should not
be construed as an endorsement of any kind.
 
5/29/2003